InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 11.67 billion. The enterprise value is 5.56 billion.
Market Cap | 11.67B |
Enterprise Value | 5.56B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
Earnings Date | Mar 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has increased by 0.57% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.76B |
Shares Change (YoY) | +0.57% |
Shares Change (QoQ) | +26.66% |
Owned by Insiders (%) | 21.35% |
Owned by Institutions (%) | 23.53% |
Float | 1.09B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 9.63 |
PB Ratio | 1.41 |
P/TBV Ratio | 1.61 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -13.37 |
EV / Sales | 5.59 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.15 |
Financial Position
The company has a current ratio of 7.74, with a Debt / Equity ratio of 0.23.
Current Ratio | 7.74 |
Quick Ratio | 7.27 |
Debt / Equity | 0.23 |
Debt / EBITDA | n/a |
Debt / FCF | -2.20 |
Interest Coverage | -24.89 |
Financial Efficiency
Return on equity (ROE) is -5.52% and return on invested capital (ROIC) is -4.88%.
Return on Equity (ROE) | -5.52% |
Return on Assets (ROA) | -4.03% |
Return on Capital (ROIC) | -4.88% |
Revenue Per Employee | 914,299 |
Profits Per Employee | -381,930 |
Employee Count | 1,089 |
Asset Turnover | 0.09 |
Inventory Turnover | 1.19 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.42% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -16.42% |
50-Day Moving Average | 6.53 |
200-Day Moving Average | 5.40 |
Relative Strength Index (RSI) | 31.67 |
Average Volume (20 Days) | 3,466,450 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 995.67 million and -415.92 million in losses. Loss per share was -0.24.
Revenue | 995.67M |
Gross Profit | 856.57M |
Operating Income | -696.34M |
Pretax Income | -432.20M |
Net Income | -415.92M |
EBITDA | -615.91M |
EBIT | -696.34M |
Loss Per Share | -0.24 |
Balance Sheet
The company has 7.85 billion in cash and 1.71 billion in debt, giving a net cash position of 6.13 billion or 3.48 per share.
Cash & Cash Equivalents | 7.85B |
Total Debt | 1.71B |
Net Cash | 6.13B |
Net Cash Per Share | 3.48 |
Equity (Book Value) | 7.56B |
Book Value Per Share | 3.98 |
Working Capital | 7.59B |
Cash Flow
In the last 12 months, operating cash flow was -611.94 million and capital expenditures -165.91 million, giving a free cash flow of -777.85 million.
Operating Cash Flow | -611.94M |
Capital Expenditures | -165.91M |
Free Cash Flow | -777.85M |
FCF Per Share | -0.44 |
Margins
Gross margin is 86.03%, with operating and profit margins of -69.94% and -41.77%.
Gross Margin | 86.03% |
Operating Margin | -69.94% |
Pretax Margin | -43.41% |
Profit Margin | -41.77% |
EBITDA Margin | -61.86% |
EBIT Margin | -69.94% |
FCF Margin | n/a |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.57% |
Shareholder Yield | -0.57% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 2.21. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.21 |
Piotroski F-Score | n/a |